Welcome to LookChem.com Sign In|Join Free
  • or

Encyclopedia

10,13-dimethyl-17-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate

Base Information Edit
  • Chemical Name:10,13-dimethyl-17-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate
  • CAS No.:53-43-0
  • Molecular Formula:C19H28O2
  • Molecular Weight:288.43
  • Hs Code.:29372900
  • NSC Number:755876
  • ChEMBL ID:CHEMBL3039094
  • Mol file:53-43-0.mol
10,13-dimethyl-17-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate

Synonyms:Spectrum_001089;Spectrum2_001130;Spectrum3_001280;Spectrum4_000244;Spectrum5_000703;BSPBio_002880;KBioGR_000648;KBioSS_001569;SPECTRUM270029;SCHEMBL370342;SPBio_000999;CHEMBL3039094;KBio2_001569;KBio2_004137;KBio2_006705;KBio3_002380;Dehydro Epiandrosterone 3-Acetate;HMS1922F18;Pharmakon1600-00270029;CCG-40086;NSC755876;NSC-755876;NCGC00178411-01;SBI-0207089.P001;AB01563185_01;AA-504/07224052;10,13-dimethyl-17-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate

Suppliers and Price of 10,13-dimethyl-17-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate
Supply Marketing:Edit
Business phase:
The product has achieved commercial mass production*data from LookChem market partment
Manufacturers and distributors:
  • Manufacture/Brand
  • Chemicals and raw materials
  • Packaging
  • price
  • Usbiological
  • DHEA
  • 48Tests
  • $ 588.00
  • Usbiological
  • Dehydroepiandrosterone
  • 1mg
  • $ 566.00
  • Usbiological
  • Dehydroepiandrosterone
  • 96Tests
  • $ 1318.00
  • Usbiological
  • Dehydroepiandrosterone
  • 96Tests
  • $ 1025.00
  • Usbiological
  • Dehydroepiandrosterone
  • 1mg
  • $ 538.00
  • Usbiological
  • Dehydroepiandrosterone
  • 1mg
  • $ 538.00
  • Usbiological
  • Dehydroepiandrosterone
  • 1mg
  • $ 538.00
  • Usbiological
  • DHEA
  • 500ul
  • $ 393.00
  • Usbiological
  • Dehydro Epiandrosterone
  • 10mg
  • $ 319.00
  • Sigma-Aldrich
  • trans-Dehydroandrosterone ≥99%
  • 25g
  • $ 299.00
Total 315 raw suppliers
Chemical Property of 10,13-dimethyl-17-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate Edit
Chemical Property:
  • Appearance/Colour:white fine crystalline powder 
  • Vapor Pressure:4.54E-09mmHg at 25°C 
  • Melting Point:149-151 °C(lit.) 
  • Refractive Index:1.56 
  • Boiling Point:426.7 °C at 760 mmHg 
  • PKA:15.02±0.60(Predicted) 
  • Flash Point:182.1 °C 
  • PSA:37.30000 
  • Density:1.12 g/cm3 
  • LogP:3.87920 
  • Storage Temp.:Hormones 
  • Solubility.:insoluble in H2O; ≥13.7 mg/mL in DMSO; ≥58.6 mg/mL in ETOH 
  • Water Solubility.:21.8mg/L(23.5 oC) 
  • XLogP3:3.8
  • Hydrogen Bond Donor Count:0
  • Hydrogen Bond Acceptor Count:3
  • Rotatable Bond Count:2
  • Exact Mass:330.21949481
  • Heavy Atom Count:24
  • Complexity:606
Purity/Quality:

99% *data from raw suppliers

DHEA *data from reagent suppliers

Safty Information:
  • Pictogram(s): IrritantXi 
  • Hazard Codes:Xi,T,F 
  • Statements: 36/37/38-39/23/24/25-23/24/25-11 
  • Safety Statements: 26-36-24/25-45-36/37-16-7 
MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:
  • Canonical SMILES:CC(=O)OC1CCC2(C3CCC4(C(C3CC=C2C1)CCC4=O)C)C
  • Isomeric SMILES:CC(=O)O[C@H]1CC[C@@]2(C3CC[C@]4(C(C3CC=C2C1)CCC4=O)C)C
  • Bone Loss Prevention Subsequent trials have examined prasterone as a treatment to limit bone loss in women with SLE.
    Studies have shown that prasterone can increase bone mineral density in patients who have been taking glucocorticoids for six months or longer, compared to placebo.
  • Investigation for Systemic Lupus Erythematosus (SLE) Prasterone, a synthetic dehydroepiandrosterone product, has been investigated for use in women with SLE who are taking glucocorticoids. Initial trials focused on improving disease activity and symptoms in women with mild to moderate SLE, but the FDA did not approve prasterone's labeling for these indications.
  • Potential Drug Interactions Prasterone may interact with 5-alpha reductase inhibitors and exhibit additive or antagonistic effects with androgens, estrogens, oral contraceptives, and progestins.
  • Dosage In clinical trials, oral prasterone dosages of 100鈥?200 mg/day were administered, resulting in supraphysiological hormone levels.
  • Intravaginal Use Intravaginal prasterone, marketed as Intrarosa庐, is approved for the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women with moderate to severe symptoms.
    Clinical trials have demonstrated that intravaginal prasterone significantly improves signs and symptoms of VVA, including dyspareunia, compared to placebo.
    Prasterone is generally well-tolerated, with the most common adverse event being application site discharge.
    Serum concentrations of estrogenic and androgenic metabolites of DHEA increased during treatment with intravaginal prasterone but remained within normal postmenopausal ranges.
Technology Process of 10,13-dimethyl-17-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate

There total 141 articles about 10,13-dimethyl-17-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:
Guidance literature:
With sodium hydroxide; In methanol;
DOI:10.3109/14756366.2015.1070843
Refernces Edit

A total synthesis of OSW-1

10.1021/jo7018812

The research focuses on the total synthesis of OSW-1, a natural saponin with significant antitumor activities, which was synthesized from (+)-dehydroisoandrosterone, L-arabinose, and D-xylose on a gram scale. The study aimed to develop a new, efficient, and practical method for synthesizing OSW-1, a promising lead compound for the development of novel antitumor drugs, due to its potent cytotoxicity against various malignant tumor cells. The synthesis was achieved in 10 linear steps with an overall yield of 6.4%, starting from (+)-dehydroisoandrosterone. The research concluded that the developed synthetic strategy was reliable, with simple workup procedures, enabling large-scale synthesis and providing a foundation for the preparation of various OSW-1 derivatives for further studies on structure-activity relationships and potential anticancer therapeutics. Key chemicals used in the process included propanenitrile, 3-methylbutylmagnesium bromide, NaOH, TBS chloride, ethylene glycol, and a variety of other reagents and solvents employed in the multi-step synthesis procedure.

Influence of substrate structure on the catalytic efficiency of hydroxysteroid sulfotransferase STa in the sulfation of alcohols

10.1021/tx950065t

The research investigates the quantitative relationships between substrate structure and the catalytic activity of sulfotransferase a (STa), an enzyme that catalyzes the formation of sulfuric acid esters from alcohols. The study aims to understand the specificity of STa for various alcohols, including both endogenous and xenobiotic compounds. Key chemicals involved in the research include benzyl alcohol and a series of benzylic alcohols substituted with n-alkyl groups (CnH2n+1, where n ranges from 1 to 8), primary n-alkanols (CnH2n+1OH, where n ranges from 3 to 16), and various other alcohols such as cholesterol, dehydroepiandrosterone (DHEA), and several phenols. The researchers also used 7-(hydroxymethyl)-12-methylbenz[a]anthracene (HMBA) to study the enzyme's activity with a carcinogenic compound. The study employed methods such as purification of STa, determination of kinetic constants (kcat/Km values), and molecular modeling to analyze the influence of substrate hydrophobicity and steric effects on the catalytic efficiency of STa. The findings revealed that hydrophobicity of the substrate is a major factor contributing to the catalytic efficiency, with optimal catalytic efficiency observed for certain chain lengths of aliphatic alcohols and benzylic alcohols. The study also highlighted limitations in substrate size and the importance of steric effects, providing insights into the enzyme's specificity for different alcohols.

Synthesis of imidazole-derived steroidal hybrids as potent aromatase inhibitors

10.1007/s00044-012-0059-1

The study investigates the creation and evaluation of imidazolyl substituted 16E-arylidenosteroidal derivatives for their potential as aromatase inhibitors, which are crucial in treating estrogen-dependent tumors such as breast cancer. The researchers synthesized various steroidal hybrids by condensing imidazole with the androstane nucleus. Key chemicals involved include dehydroepiandrosterone (DHA), substituted benzaldehydes, and imidazole. The synthesis process involved aldol condensation of DHA with substituted benzaldehydes to form 16-benzylidene steroidal derivatives, which were then fused with imidazole and subjected to Oppenauer oxidation to yield the final products. The most potent compound, 16-[3-{3-(imidazol-1-yl)propoxy}benzylidene]-4-androstene-3,17-dione (10), exhibited an IC50 value of 4.4 μM, making it seven times more potent than the standard drug aminoglutethimide. The study highlights the significance of structural modifications in enhancing the binding affinity of these steroidal derivatives with the aromatase enzyme, with meta-substituted compounds showing more promise than para-substituted ones.

Post RFQ for Price